We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
+11.52%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$240M
AUM Growth
+$14.4M
Cap. Flow
+$14.7M
Cap. Flow %
6.13%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$16.8M

Top Sells

Rank Stock Value
1
NRX
NEPHROGENEX INC COM
NRX
+$2.15M

Sector Composition

Rank Sector Weight
1 Technology 27.98%
2 Healthcare 17.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IL
1
DELISTED
IntraLinks Holdings Inc.
IL
$67.1M 27.98%
6,490,503
– –
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$61.8M 25.76%
1,067,892
– –
EVDY
3
DELISTED
Everyday Health, Inc.
EVDY
$52.8M 22.02%
4,107,522
– –
TVRD
4
Tvardi Therapeutics
TVRD
$23.5M
$26.8M 11.18%
74,113
– –
RCKT icon
5
Rocket Pharmaceuticals
RCKT
$353M
$15.6M 6.49%
+717,646
New +$16.8M
NRX
6
DELISTED
NEPHROGENEX INC COM
NRX
$8.29M 3.46%
1,052,966
-273,860
-21% -$2.15M
RLOC
7
DELISTED
REACHLOCAL INC COM STK (DE)
RLOC
$7.48M 3.12%
2,570,395
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q1 2015 Portfolio in Review

As of Q1 2015, Rho Capital Partners held 7 positions worth $240M, up 6.4% from $225M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners deployed $14.7M of net new capital in Q1 2015, opening 1 new position. Its largest new stake was Rocket Pharmaceuticals: 717,646 shares worth $15.6M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 34% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was NEPHROGENEX INC COM, an estimated $2.15M trimmed.

  • Rho Capital Partners's largest Q1 2015 buy was Rocket Pharmaceuticals: 717,646 shares worth $15.6M.
  • Rho Capital Partners's biggest Q1 2015 reduction was NEPHROGENEX INC COM, cutting an estimated $2.15M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $240M portfolio in Q1 2015.
  • Rho Capital Partners opened 1 new position and closed 0 in Q1 2015.
  • Rho Capital Partners's portfolio value rose 6.4% quarter-over-quarter to $240M.

Based on Rho Capital Partners's 13F filing for Q1 2015, filed 17 Apr 2015.